Earnings

Velo3D 2025 Financial Performance Review

Velo3D 2025 Financial Performance Review

Velo3D, Inc. is an additive manufacturing technology company that transforms aerospace and defense supply chains with metal 3D printing. Full-year…

Fennec Pharmaceuticals 2025 Financial Update

Fennec Pharmaceuticals Inc. is a specialty pharmaceutical company committed to the fight against ototoxicity in cancer patients. The company recently…

Core & Main, Inc. (CNM) Q4 Earnings: Misses on EPS, Revenue Recap

Significant earnings miss. Core & Main, Inc. (CNM) reported Q4 2025 adjusted earnings of $0.52 per share, falling well short…

Avalo Therapeutics 2025 Financial Review

Avalo Therapeutics is a clinical-stage biotechnology company dedicated to developing IL-1β-based treatments for immune-mediated inflammatory diseases. The company's lead asset,…

WeRide Inc. 2025 Financial Performance Review

WeRide Inc. is a global leader in autonomous driving technology and the first publicly traded robotaxi company. For the full…

Surrozen 2025 Financial Results Review

Surrozen is a biotechnology company developing targeted therapeutics that harness Wnt signaling to address sight-threatening ophthalmic conditions. For the full…

PPHC Q4 and FY 2025 Financial Review

Public Policy Holding Company, Inc. (PPHC) is a global strategic communications provider offering advisory services across Government Relations, Corporate Communications,…

Cabaletta Bio Q4 and FY 2025 Financial Review

Cabaletta Bio is a late-stage clinical biotechnology company focused on developing targeted cell therapies specifically for patients with autoimmune diseases.…

Arbutus Biopharma 2025 Financial Review

Arbutus Biopharma Corporation is a clinical-stage biopharmaceutical company focused on infectious diseases. For the year ended December 31, 2025, Arbutus…

Sutro Biopharma 2025 Financial Review

Sutro Biopharma is a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs). For the year ended December…